Ya‐Zhen Qin - Concepedia

Author

Ya‐Zhen Qin

Peking University

Also Known As

Qin Y, Qin Ya-Zhen, Qin Ya-zhen, Qin Yazhen, Qin Ya‐Zhen, Qin, Ya-Zhen, Y Qin, Y Z Qin, Y. Qin, Y. Z. QIN

246

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Peking University Peking University People's Hospital Center for Life Sciences Chinese Academy of Medical Sciences & Peking Union Medical College Soochow University

About

Ya‐Zhen Qin is an author at Peking University specializing in medicine, hematology, and molecular diagnostics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	32	948
2	Health Sciences	9	9	284
3	Engineering	3	3	81
4	Natural Sciences	2	2	68
5	Biostatistics	1	1	33

Ya‐Zhen Qin

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial Hong‐Hu Zhu, Xiaohui Zhang, Ya‐Zhen Qin, Blood	2013	321
Risk stratification–directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation Chen‐Hua Yan, Dai‐Hong Liu, Kai‐Yan Liu, Blood	2012	288
In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification Yu Wang, Depei Wu, Qifa Liu, Blood	2014	128
Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia Huan Chen, Kai‐Yan Liu, Lan‐Ping Xu, Journal of Hematology & Oncology	2012	103
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial Qian Jiang, Zongru Li, Ya‐Zhen Qin, Journal of Hematology & Oncology	2022	90
Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity Xiao‐Su Zhao, Chen‐Hua Yan, Dai‐Hong Liu, Annals of Hematology Flow Cytometry MonitoringLymphoid NeoplasiaOncologyMedicineImmunology	2013	89
Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase Qian Jiang, Lan‐Ping Xu, Dai‐Hong Liu, Blood	2011	82
Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease Ya‐Zhen Qin, Hong‐Hu Zhu, Bin Jiang, Leukemia Research Hematological MalignancyMedicineExpression PatternsMixed-phenotype Acute LeukemiaHematology	2008	80
Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: A comprehensive large-scale study from a single Chinese center Ya‐Zhen Qin, Hong‐Hu Zhu, Qian Jiang, Leukemia Research Hematological MalignancyC-kit MutationsOncologyHealth SciencesMedicine	2014	75
The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia Ya‐Zhen Qin, Yu Wang, Lan‐Ping Xu, Journal of Hematology & Oncology	2017	63

Page 1